These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 24431398)

  • 1. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
    Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).
    Virkki LM; Valleala H; Takakubo Y; Vuotila J; Relas H; Komulainen R; Koivuniemi R; Yli-Kerttula U; Mali M; Sihvonen S; Krogerus ML; Jukka E; Nyrhinen S; Konttinen YT; Nordström DC
    Clin Rheumatol; 2011 Nov; 30(11):1447-54. PubMed ID: 21644062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
    Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
    Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.
    Simard JF; Neovius M; Askling J;
    Arthritis Rheum; 2012 Nov; 64(11):3502-10. PubMed ID: 22886739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
    Canhão H; Rodrigues AM; Mourão AF; Martins F; Santos MJ; Canas-Silva J; Polido-Pereira J; Pereira Silva JA; Costa JA; Araújo D; Silva C; Santos H; Duarte C; da Silva JA; Pimentel-Santos FM; Branco JC; Karlson EW; Fonseca JE; Solomon DH
    Rheumatology (Oxford); 2012 Nov; 51(11):2020-6. PubMed ID: 22843791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A; Dougados M; Mariette X; Cantagrel A; Deschamps V; Flipo RM; Logeart I; Schaeverbeke T; Sibilia J; Le Loët X; Combe B
    Joint Bone Spine; 2014 Jul; 81(4):352-9. PubMed ID: 24721422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.